Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with or without sunitinib in platinum-refractory metastatic non-small cell lung cancer
2005-006022-29Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sunitinib and erlotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2006; status: completed.
02
Drugs
sunitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-006022-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006022-29.